Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

Phase 3

Completed

Conditions: Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Doxorubicin
Drug: Prednisone
Drug: Bendamustine

First Posted Date: 2013-06-28

Last Posted Date: 2020-08-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 159

Registration Number: NCT01889069

Locations: 🇮🇹
Az. Osp. Carlo Poma; Divisione Di Oncologia Medica, Mantova, Lombardia, Italy
🇮🇹
Seconda università degli studi di napoli; Medicina clinica e sperimentale magrassi - lanzara, Napoli, Campania, Italy
🇮🇹
ASST DI CREMA; U O Oncologia Medica, Crema, Lombardia, Italy

and more 36 locations

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Phase 3

Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: erlotinib
Drug: placebo
Drug: onartuzumab

First Posted Date: 2013-06-27

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 10

Registration Number: NCT01887886

An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam

Terminated

Conditions: Hepatitis B, Chronic

First Posted Date: 2013-06-25

Last Posted Date: 2016-06-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 16

Registration Number: NCT01886300

A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome

Phase 2

Terminated

Conditions: Myelodysplastic Syndromes, Myelogenous Leukemia, Acute

Interventions: Drug: cytarabine
Drug: vismodegib

First Posted Date: 2013-06-19

Last Posted Date: 2015-12-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 38

Registration Number: NCT01880437

A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs

Phase 4

Withdrawn

Conditions: Rheumatoid Arthritis

Interventions: Drug: methotrexate
Drug: tocilizumab [RoActemra/Actemra]

First Posted Date: 2013-06-14

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT01878318

Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: RXDX-105

First Posted Date: 2013-06-14

Last Posted Date: 2019-04-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 143

Registration Number: NCT01877811

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown, Washington, District of Columbia, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
University Cancer & Blood Center, LLC, Athens, Georgia, United States

and more 11 locations

A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Lebrikizumab
Drug: Standard of Care
Drug: Placebo

First Posted Date: 2013-06-11

Last Posted Date: 2017-05-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 348

Registration Number: NCT01875003

Locations: 🇺🇸
Allergy & Asthma Consultants, Redwood City, California, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
The Clinical Research Center, Shiloh, Illinois, United States

and more 161 locations

A Study of Three Modified-Release Formulations of RO4917523 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: RO4917523

First Posted Date: 2013-06-10

Last Posted Date: 2015-09-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 24

Registration Number: NCT01873508

A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Alectinib

First Posted Date: 2013-06-07

Last Posted Date: 2018-08-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 134

Registration Number: NCT01871805

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, Commack, New York, United States
🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸
UCLA, Los Angeles, California, United States

and more 39 locations

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Lebrikizumab
Drug: Pirfenidone
Drug: Placebo

First Posted Date: 2013-06-07

Last Posted Date: 2018-08-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 505

Registration Number: NCT01872689

Locations: 🇺🇸
Pulmonary Consultants, Tacoma, Washington, United States
🇦🇺
Box Hill Hospital; Eastern Clinical Research Unit, Box Hill, Victoria, Australia
🇫🇷
Hopital Bichat Claude Bernard ; Service de Pneumologie, Paris, France

and more 109 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy